Indications for AFLURIA QUADRIVALENT:
Adults and Children:
<6mos: not established. Give by IM inj once in the anterolateral thigh (6–11mos) or in the deltoid (≥12mos). May be administered by needle and syringe (≥6mos) or PharmaJet Stratis Needle-Free Injection System (18–64yrs only); see full labeling. If 2 doses, give at least 1 month apart. 6–35mos: 1 or 2 doses (0.25mL) depending on vaccination history as per annual ACIP recommendation. 36mos–8yrs: 1 or 2 doses (0.5mL) depending on vaccination history as per annual ACIP recommendation. ≥9yrs: 1 dose (0.5mL).
AFLURIA QUADRIVALENT Contraindications:
Allergy to egg protein. Life-threatening reaction to any previous flu vaccine.
AFLURIA QUADRIVALENT Warnings/Precautions:
Use current formulation only. Have appropriate medical treatment and supervision readily available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunocompromised. Pregnancy. Nursing mothers.
AFLURIA QUADRIVALENT Classification:
AFLURIA QUADRIVALENT Interactions:
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants: may get suboptimal response.
Local reactions (eg, tenderness, redness, swelling, pain, itching, bruising), headache, myalgia, malaise, fatigue, irritability, diarrhea, loss of appetite.
Generic Drug Availability:
Single-dose prefilled syringe 0.25mL, 0.5mL (preservative-free)—10 (without needles); Multi-dose vial 5mL (contains thimerosal)—1